Author:
Vizza Patrizia,Aracri Federica,Guzzi Pietro Hiram,Gaspari Marco,Veltri Pierangelo,Tradigo Giuseppe
Abstract
AbstractProteomic-based analysis is used to identify biomarkers in blood samples and tissues. Data produced by devices such as mass spectrometry requires platforms to identify and quantify proteins (or peptides). Clinical information can be related to mass spectrometry data to identify diseases at an early stage. Machine learning techniques can be used to support physicians and biologists in studying and classifying pathologies. We present the application of machine learning techniques to define a pipeline aimed at studying and classifying proteomics data enriched using clinical information. The pipeline allows users to relate established blood biomarkers with clinical parameters and proteomics data. The proposed pipeline entails three main phases: (i) feature selection, (ii) models training, and (iii) models ensembling. We report the experience of applying such a pipeline to prostate-related diseases. Models have been trained on several biological datasets. We report experimental results about two datasets that result from the integration of clinical and mass spectrometry-based data in the contexts of serum and urine analysis. The pipeline receives input data from blood analytes, tissue samples, proteomic analysis, and urine biomarkers. It then trains different models for feature selection, classification and voting. The presented pipeline has been applied on two datasets obtained in a 2 years research project which aimed to extract hidden information from mass spectrometry, serum, and urine samples from hundreds of patients. We report results on analyzing prostate datasets serum with 143 samples, including 79 PCa and 84 BPH patients, and an urine dataset with 121 samples, including 67 PCa and 54 BPH patients. As results pipeline allowed to identify interesting peptides in the two datasets, 6 for the first one and 2 for the second one. The best model for both serum (AUC=0.87, Accuracy=0.83, F1=0.81, Sensitivity=0.84, Specificity=0.81) and urine (AUC=0.88, Accuracy=0.83, F1=0.83, Sensitivity=0.85, Specificity=0.80) datasets showed good predictive performances. We made the pipeline code available on GitHub and we are confident that it will be successfully adopted in similar clinical setups.
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Zhou X, Mao J, Ai J, Deng Y, Roth MR, Pound C, et al. Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics. PLoS ONE. 2012;7:e48889.
2. Vizza P, Pascuzzi L, Aracri F, Tavolaro E, Lambardi P, Gaspari M, et al. Prostate Cancer Disease Study by Integrating Peptides and Clinical Data. In: AAI4H@ ECAI. Amsterdam: IOS Press; 2020. p. 45–48.
3. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med. 1993;118(10):793–803.
4. Pierre-Victor D, Parnes HL, Andriole GL, Pinsky PF. Prostate cancer incidence and mortality following a negative biopsy in a population undergoing PSA screening. Urology. 2021;155:62–9.
5. White CN, Chan DW, Zhang Z. Bioinformatics strategies for proteomic profiling. Clin Biochem. 2004;37(7):636–41.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献